Novartis, Bayer and Boehringer Ingelheim to showcase their commitment to a reimagined pharma industry

Reuters Events 11 - 22 October, 2021, Virtual
Board level executives from Novartis, Bayer and Boehringer Ingelheim, amongst many more, will showcase their long-term visions for healthcare as a response to the COVID-19 pandemic, by joining the speaker faculty at Reuters Events Pharma Europe 2021.

Reuters Events will bring together another 150 life sciences leaders as speakers, and thousands more executive attendees, to showcase the investments being made as the industry accelerates its digital transformation platform to ensure changes are embedded for long-term value for physicians and patients alike.

Blair Gottscho, Managing Director - Pharma, Reuters Events, said the pharma industry had responded well to the challenges of the pandemic, re-assessed operating models, and have found new ways to deliver for physicians, clinicians, providers, payers and patients alike.

"There is significant investment happening across the industry - in both people and technology - to create long-lasting, integrated and flexible systems and processes, that are helping to build a more sustainable healthcare systems.

"We're proud to be showcasing the best and brightest at Pharma Europe 2021. This is the global home for industry executives to set strategy post-pandemic.” Along with this investment, the industry is experiencing an acceleration in collaboration between functions within organizations. However, the environment for collaboration extends beyond company walls, as companies are increasingly forming partnerships that build value for all healthcare stakeholders.

Josh Bramwell, Head of Europe, Reuters Events, said the industry had stepped up to the challenges that the pandemic has created.

“Companies are now seeing collaboration as a competitive advantage," Bramwell said.

"They've looked to optimise pre-competitive opportunities with industry partners, foster long-term stakeholder partnerships to provide real-world patient value, and remove function silos to deliver an agile and efficient business model. These are the case studies that we'll be highlighting on stage at Pharma Europe 2021."

Reuters Events Pharma Europe has been running for 18 years and was previously known as eyeforpharma Barcelona.

You can learn more about Pharma Europe here: https://reutersevents.com/events/barcelona/

Most Popular Now

COVID-19 vaccine protection wanes after three mont…

The protection offered by the Oxford-Astra Zeneca COVID-19 vaccine declines after three months of receiving two doses, a study says. The findings - drawn from datasets...

New study adds more evidence for Omicron immune ev…

A new study from Columbia researchers, in collaboration with scientists at the University of Hong Kong, adds more evidence that the omicron variant can evade the immune p...

European Commission grants conditional marketing a…

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announce...

Stopping dementia at the nose with combination of …

Dementia is thought to occur when proteins called amyloid-β, tau, and α-synuclein accumulate in the brain and form oligomers. A research group from the Department of Tran...

Vaxzevria significantly boosted antibody levels ag…

AstraZeneca's Vaxzevria (ChAdOx1-S [Recombinant]) significantly boosted levels of antibodies against the Omicron SARS-CoV-2 variant (B.1.1.529) following a third dose boo...

Treatments in weeks, not months: Scientists develo…

An international team of scientists has created a plan for an accelerated pipeline for developing drug cocktails to battle the COVID-19 pandemic. The pipeline could speed...

Scientists identify antibodies that can neutralize…

An international team of scientists have identified antibodies that neutralize omicron and other SARS-CoV-2 variants. These antibodies target areas of the virus spike pro...

COVID-19 can trigger self-attacking antibodies

Infection with the virus that causes COVID-19 can trigger an immune response that lasts well beyond the initial infection and recovery - even among people who had mild sy...

Leiden University Medical Center and Intravacc to …

Intravacc, a global leader in translational research and development of therapeutic vaccines and vaccines against infectious diseases, today announced a partnership with ...

Pfizer and BioNTech sign new global collaboration …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a new research, development and commercialization collaboration to develop a potential first mRNA-based v...

AstraZeneca and Ionis close agreement to develop a…

AstraZeneca has closed a global development and commercialisation agreement with Ionis Pharmaceuticals, Inc. (Ionis) for eplontersen, formerly known as IONIS-TTR-LRX. ...

COVID-19 - Omicron: resistant to most monoclonal a…

The Omicron variant was detected for the first time in South Africa in November 2021 and has since spread to many countries. It is expected to become the dominant variant...